



(51) International Patent Classification:

C07K 16/16 (2006.01) C07K 16/28 (2006.01)
A61P 35/04 (2006.01)

(21) International Application Number:

PCT/US2023/063766

(22) International Filing Date:

06 March 2023 (06.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/317,160 07 March 2022 (07.03.2022) US

(71) Applicant: **ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED** [CN/CN]; 136 Des Voeux Road Central, 15/F, BOC Group Life Assurance Tower, Central Hong Kong, Hong Kong (CN).

(72) Inventor; and

(71) Applicant (for US only): **CHEN, Hung-Kai** [US/US]; 1507 Richardson Ave., Los Altos, California 94024 (US).

(72) Inventors: **HSIAO, Huey-Wen**; c/o ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED, 136 Des Voeux Road Central, 15/F, BOC Group Life Assur-


ance Tower, Central Hong Kong, Hong Kong (CN). **KONI, Pandelakis Andreas**; c/o ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED, 136 Des Voeux Road Central, 15/F, BOC Group Life Assurance Tower, Central Hong Kong, Hong Kong (CN). **CHUNG, Pei-Han**; c/o ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED, 136 Des Voeux Road Central, 15/F, BOC Group Life Assurance Tower, Central Hong Kong, Hong Kong (CN).

(74) Agent: **WHITING, Adam K.**; 4100 Redwood Rd 20A-203, Oakland, California 94619 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANTI-CD36 ANTIBODIES AND USES THEREOF

FIG. 10A



(57) Abstract: The present disclosure provides antibodies which specifically bind to human CD36 protein (hCD36) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects and/or ligand transport into cells mediated by CD36. Examples of CD36-mediated effects, among others, may include oxidized lipid transport into CD8 T cells potentially causing cell death and fatty acid transport in regulatory T cells increasing their survival and immune suppression in the tumor micro-environment (TME). The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat various diseases and conditions responsive to decreasing, inhibiting and/or blocking CD36-dependent ligand transport into cells.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*